Map
GAIA
NK-like cell
platform
A breakthrough in
eliminating solid tumors
A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.
GAIA's antibody-anchoring
and activating peptide
A peptide-based platform
to generate GAIA NK-like cells
targeting a variety of tumors
GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.
Core Technology II
News
-
News
At the 38th Annual Meeting of Society of Immunotherapy of Cancer (SITC2023), Interim Report of Phase I Clinical Trial of Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102
More -
News
At the 38th Society for Immunotherapy of Cancer (SITC 2023), an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.
More -
News
At the Asian Oncology Society 2023 (AOS 2023), an interim report on the Phase I/II trial of GAIA-102 for patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites was presented.
More -
News
At the 65th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.
More -
News
Cellab Healthcare Service (Cellab HS) and GAIA BioMedicine (GAIA) jointly held a press conference to announce that the two firms had executed a business agreement concerning the production of GAIA-102.
More